Dr. Charles Frederick Degenhardt III, MD

Dr. Degenhardt practices at Articularis Healthcare Group Inc. in Savannah, Georgia.

Dr. Degenhardt's NPI, 1467651711, was assigned on July 17, 2007. Dr. Degenhardt graduated from University of South Carolina School of Medicine in 2007. Dr. Degenhardt holds Georgia license 70547.

Dr. Degenhardt's primary practice is Articularis Healthcare Group Inc., at 5400 Waters Ave, Savannah, GA 31404 in Chatham County. The practice phone is (912) 349-4227.

Dr. Degenhardt's primary practice is Articularis Healthcare Group Inc. in Savannah, Georgia. Dr. Degenhardt is also affiliated with Memorial Health University Medical Center. The medical group on file is CORA Physical Therapy - Bluffton. Dmand AI also links Dr. Degenhardt to 4 more hospitals, 3 medical groups, 2 group practices and clinics, 2 therapy and rehab clinics and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Degenhardt practices, 10 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Degenhardt's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Degenhardt's licenses on file in 3 states: Georgia, Florida and South Carolina.

CMS data shows 196,187 Medicare services from Dr. Degenhardt across 31 procedure codes in 2024, for 793 Medicare patients. Medicare paid $2,411,828 for them. Every service was in an office.

CMS counts 793 Medicare patients who saw Dr. Degenhardt in 2024. The largest group is 65 to 74, with 394 patients. 75% of them have arthritis, and 75% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Degenhardt's median patient age at 64, with 77% women.

In 2024, Dr. Degenhardt wrote 1,774 Medicare Part D claims for 446 patients. 82% of them were for generic drugs. CMS names the drug for 1,579 of them, across 26 drugs with 11 or more claims each, at $1,416,260 in total drug cost. In 2023, CMS named 1,445 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Degenhardt for performance year 2024, reported through an alternative payment model (APM). Dr. Degenhardt accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1,034 general payments to Dr. Degenhardt from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Amgen Inc. paid the most, $2,783.

Dr. Degenhardt graduated from University of South Carolina School of Medicine in 2007.